Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Transcept Pharmaceuticals to Present at the BIO Investor Forum on October 26, 2011

October 24, 2011

POINT RICHMOND, Calif., Oct. 24, 2011 /PRNewswire/ — Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that Transcept management is scheduled to present at the BIO Investor Forum in San Francisco on October 26, 2011 at 9:30 a.m. PT.

A live audio webcast and replay of this presentation may be accessed at http://tinyurl.com/42ptb8x and on the Transcept Investor webpage at www.transcept.com.

About Transcept

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Transcept is developing Intermezzo® (zolpidem tartrate sublingual tablet) as a prescription sleep aid for use as needed when a middle of the night awakening is followed by difficulty returning to sleep. Transcept and Purdue Pharmaceutical Products L.P. are parties to a collaboration agreement for the development and commercialization of Intermezzo® in the United States. Transcept is also developing TO-2061, a low dose ondansetron augmentation therapy for patients with obsessive compulsive disorder (OCD) who have not adequately responded to treatment with approved first-line pharmacotherapy. For further information, please visit the Transcept website at: www.transcept.com.

Contact:
Transcept Pharmaceuticals, Inc.
Greg Mann
Director, Corporate Communications
(510) 215-3567
gmann@transcept.com

SOURCE Transcept Pharmaceuticals, Inc.


Source: PR Newswire